查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1618754

非何杰金氏淋巴瘤治疗市场：按治疗类型、应用和最终用户划分 - 全球预测 2025-2030

Non-Hodgkin Lymphoma Treatment Market by Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy), Application (Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

非何杰金氏淋巴瘤治疗市场2023年估值为82亿美元，预计到2024年将达到88.4亿美元，复合年增长率为7.91%，到2030年将达到139.8亿美元。

非何杰金氏淋巴瘤（NHL）治疗市场范围涵盖NHL各种亚型的诊断、治疗和管理，重点在于化疗、免疫治疗、标靶治疗和放射线治疗等药物介入。与寻求有效和创新治疗方法的医疗保健提供者、製药公司、研究人员和患者相关。非何杰金氏淋巴瘤的盛行率以及对长期有效治疗方案的需求未得到满足，凸显了对非何杰金氏淋巴瘤治疗的需求。该市场有多种应用，包括医院、癌症研究机构和专科诊所，由于精准医疗的进步和医疗保健成本的上升，需求不断增长。最终用途范围适用于 NHL 人口统计和阶段的患者，从初始诊断到监测復发或缓解。市场洞察表明，非何杰金氏淋巴瘤盛行率的不断上升、生物技术的进步以及新治疗方案的核准正在影响这一增长。高治疗成本、治疗相关副作用以及 NHL 亚型的复杂性等挑战为患者获得一致的治疗结果带来了障碍。 CAR T 细胞疗法和双特异性抗体的出现显示出提高疗效和个人化治疗的巨大潜力。建议的治疗方法包括投资创新疗法的研发、利用伙伴关係加强临床试验以及专注于开发具有成本效益的治疗方法。限制包括严格的法规环境和可能影响市场准入的报销问题。创新和研究的最佳领域是提高免疫疗法的疗效，整合人工智慧进行预后和治疗策略，并探索结合不同治疗方法以改善患者预后的联合治疗。非何杰金氏淋巴瘤治疗市场竞争激烈、充满活力且注重科学进步，因此企业在提高非何杰金氏淋巴瘤患者的生活品质和存活率方面具有巨大潜力。

主要市场统计
基准年[2023] 82亿美元
预计年份 [2024] 88.4亿美元
预测年份 [2030] 139.8亿美元
复合年增长率（%） 7.91%

市场动态：快速发展的非何杰金氏淋巴瘤治疗市场的关键市场洞察

非何杰金氏淋巴瘤治疗市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 非何杰金氏淋巴瘤盛行率上升
    • 有前途的淋巴瘤药物的上市和药物核准
    • 重视非何杰金氏淋巴瘤患者的预后与规范治疗
  • 市场限制因素
    • 治疗费用上涨和某些副作用
  • 市场机会
    • 增加非何杰金氏淋巴瘤治疗方法的研究和开发
    • 政府和非营利组织的投资增加
  • 市场挑战
    • 对癌症治疗方案的严格规定

波特五力：驾驭非何杰金氏淋巴瘤治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解非何杰金氏淋巴瘤治疗市场的外部影响

外部宏观环境因素在塑造非何杰金氏淋巴瘤治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解非何杰金氏淋巴瘤治疗市场的竞争格局

非何杰金氏淋巴瘤治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵非何杰金氏淋巴瘤治疗市场供应商的绩效评估

FPNV 定位矩阵是评估非何杰金氏淋巴瘤治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划非何杰金氏淋巴瘤治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，非何杰金氏淋巴瘤治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 非何杰金氏淋巴瘤发生率上升
      • 有希望的淋巴瘤药物上市和药物核准
      • 关注 NHL 患者预后和一线治疗计划的护理标准
    • 抑制因素
      • 治疗费用昂贵且有副作用
    • 机会
      • 加大疾病治疗药物的研发力度
      • 政府和非营利组织增加投资
    • 任务
      • 严格监管癌症治疗方案
  • 市场区隔分析
    • 治疗类型：化疗以防止癌症扩散到身体其他部位
    • 应用：免疫疗法和放射疗法在瀰漫性大 B 细胞淋巴瘤 (DLBCL) 的晚期治疗中的应用
    • 最终用户：医院越来越多地采用 NHL 治疗新策略
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗类型分類的非何杰金氏淋巴瘤治疗市场

  • 化疗
  • 免疫疗法
  • 放射治疗
  • 干细胞移植
  • 标靶治疗

第七章非何杰金氏淋巴瘤治疗市场：依应用分类

  • 瀰漫性大B细胞淋巴瘤
  • 滤泡性淋巴瘤
  • 套细胞淋巴瘤

第八章非何杰金氏淋巴瘤治疗市场：依最终用户分类

  • 癌症中心
  • 居家护理
  • 医院

第九章美洲非何杰金氏淋巴瘤治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太非何杰金氏淋巴瘤治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲非何杰金氏淋巴瘤治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • EPKINLY (epcolitamab-bysp) 已被美国FDA核准为第一个也是唯一一个用于治疗患有復发或难治性瀰漫性大 B 细胞淋巴瘤 (DLBCL) 的成人患者的双特异性抗体。
    • 杨森与 Cellular Biomedicine Group 签订全球合作与授权合约，开发下一代 CAR-T 疗法
    • 作为抗 CD20 合作的一部分，百健 (Biogen) 与基因泰克 (Genentech) 同意就后期双特异性抗体的潜在商业化收取特许权使用费
  • 战略分析和建议

公司名单

  • AstraZeneca PLC
  • Aurobindo Pharma
  • Bayer AG
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hetero Drugs Ltd.
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Ltd.
  • Janssen Global Services, LLC
  • Kyowa Kirin Co., Ltd.
  • Lupin Ltd.
  • Merck KGaA
  • Nordic Nanovector ASA by Thor Medical
  • Novartis AG
  • Pharmacyclics, LLC
  • Salvavidas Pharmaceutical Pvt. Ltd.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Pharmaceuticals
Product Code: MRR-036C5CF3B518

The Non-Hodgkin Lymphoma Treatment Market was valued at USD 8.20 billion in 2023, expected to reach USD 8.84 billion in 2024, and is projected to grow at a CAGR of 7.91%, to USD 13.98 billion by 2030.

The scope of the Non-Hodgkin Lymphoma (NHL) treatment market encompasses the diagnosis, treatment, and management of various subtypes of NHL, focusing on pharmacologic interventions such as chemotherapy, immunotherapy, targeted therapy, and radiation therapy. It pertains to healthcare providers, pharmaceutical companies, researchers, and patients seeking effective, innovative treatments. The necessity for NHL treatment is underscored by its prevalence and the unmet need for long-term, effective treatment options. This market has diverse applications including hospitals, cancer research institutes, and specialty clinics, with growing demand fueled by advances in precision medicine and increased healthcare expenditure. The end-use scope covers patients across demographics and stages of NHL, from initial diagnosis to relapse or remission monitoring. Market insights reveal growth influenced by the increasing incidence of NHL, advances in biotechnology, and the approval of novel treatment options. Challenges such as high treatment costs, adverse treatment-related side effects, and the complexity of NHL subtypes create hurdles for consistent patient outcomes. Opportunities arise with the advent of CAR T-cell therapy and bispecific antibodies, presenting significant potential for improved efficacy and personalized care. Recommendations include investing in R&D for innovative therapies, leveraging partnerships for enhanced clinical trials, and focusing on developing cost-effective treatment regimens. Constraints include stringent regulatory environments and reimbursement issues that may affect market accessibility. The best areas for innovation and research lie in enhancing the efficacy of immunotherapies, integrating artificial intelligence for prognosis and treatment strategies, and exploring combination therapies that combine different treatment modalities to improve patient outcomes. The NHL treatment market is competitive and dynamic, with a robust focus on scientific advancements, offering substantial potential for businesses dedicated to improving the quality of life and survival rates for NHL patients.

KEY MARKET STATISTICS
Base Year [2023] USD 8.20 billion
Estimated Year [2024] USD 8.84 billion
Forecast Year [2030] USD 13.98 billion
CAGR (%) 7.91%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Non-Hodgkin Lymphoma Treatment Market

The Non-Hodgkin Lymphoma Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of non-Hodgkin lymphoma disease
    • The launch of promising drugs and drug approval for lymphomas
    • Emphasis on NHL patient prognosis and standard of care in front-line treatment regimens
  • Market Restraints
    • High cost of the treatment and certain side effects
  • Market Opportunities
    • Increase in research and development of therapeutic drugs against the disease
    • Rising investments from government and non-profit organizations
  • Market Challenges
    • Stringent regulations for cancer treatment options

Porter's Five Forces: A Strategic Tool for Navigating the Non-Hodgkin Lymphoma Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Non-Hodgkin Lymphoma Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Non-Hodgkin Lymphoma Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Non-Hodgkin Lymphoma Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Non-Hodgkin Lymphoma Treatment Market

A detailed market share analysis in the Non-Hodgkin Lymphoma Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Non-Hodgkin Lymphoma Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Non-Hodgkin Lymphoma Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Non-Hodgkin Lymphoma Treatment Market

A strategic analysis of the Non-Hodgkin Lymphoma Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Non-Hodgkin Lymphoma Treatment Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Aurobindo Pharma, Bayer AG, Cipla Inc., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Hetero Drugs Ltd., Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Janssen Global Services, LLC, Kyowa Kirin Co., Ltd., Lupin Ltd., Merck KGaA, Nordic Nanovector ASA by Thor Medical, Novartis AG, Pharmacyclics, LLC, Salvavidas Pharmaceutical Pvt. Ltd., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Zydus Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Non-Hodgkin Lymphoma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Chemotherapy, Immunotherapy, Radiation Therapy, Stem Cell Transplantation, and Targeted Therapy.
  • Based on Application, market is studied across Diffuse Large B-cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma.
  • Based on End-User, market is studied across Cancer Centers, Home Care, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of non-Hodgkin lymphoma disease
      • 5.1.1.2. The launch of promising drugs and drug approval for lymphomas
      • 5.1.1.3. Emphasis on NHL patient prognosis and standard of care in front-line treatment regimens
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of the treatment and certain side effects
    • 5.1.3. Opportunities
      • 5.1.3.1. Increase in research and development of therapeutic drugs against the disease
      • 5.1.3.2. Rising investments from government and non-profit organizations
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations for cancer treatment options
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment type: Chemotherapy treatments to prevent the spread of cancer to other parts of the body
    • 5.2.2. Application: Utilization of immunotherapy and radiation in advanced stages treatment of diffuse large B cell lymphoma (DLBCL)
    • 5.2.3. End-user: Increasing adoption of novel strategies for NHL treatment in hospitals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Non-Hodgkin Lymphoma Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Immunotherapy
  • 6.4. Radiation Therapy
  • 6.5. Stem Cell Transplantation
  • 6.6. Targeted Therapy

7. Non-Hodgkin Lymphoma Treatment Market, by Application

  • 7.1. Introduction
  • 7.2. Diffuse Large B-cell Lymphoma
  • 7.3. Follicular Lymphoma
  • 7.4. Mantle Cell Lymphoma

8. Non-Hodgkin Lymphoma Treatment Market, by End-User

  • 8.1. Introduction
  • 8.2. Cancer Centers
  • 8.3. Home Care
  • 8.4. Hospitals

9. Americas Non-Hodgkin Lymphoma Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Non-Hodgkin Lymphoma Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. EPKINLY (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    • 12.3.2. Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies
    • 12.3.3. Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca PLC
  • 2. Aurobindo Pharma
  • 3. Bayer AG
  • 4. Cipla Inc.
  • 5. Dr. Reddy's Laboratories Ltd.
  • 6. Eli Lilly and Company
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. Gilead Sciences, Inc.
  • 9. GlaxoSmithKline PLC
  • 10. Hetero Drugs Ltd.
  • 11. Hikma Pharmaceuticals PLC
  • 12. Intas Pharmaceuticals Ltd.
  • 13. Janssen Global Services, LLC
  • 14. Kyowa Kirin Co., Ltd.
  • 15. Lupin Ltd.
  • 16. Merck KGaA
  • 17. Nordic Nanovector ASA by Thor Medical
  • 18. Novartis AG
  • 19. Pharmacyclics, LLC
  • 20. Salvavidas Pharmaceutical Pvt. Ltd.
  • 21. Sanofi S.A.
  • 22. Takeda Pharmaceutical Company Limited
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. Zydus Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. NON-HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NON-HODGKIN LYMPHOMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NON-HODGKIN LYMPHOMA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. NON-HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023